Use of Anti-Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease.
In patients with Crohn's disease (CD), anti-tumor necrosis factor (TNF) therapy is efficacious for the induction and maintenance of clinical remission, mucosal healing, reducing rates of surgery and hospitalizations, and improving health-related quality of life. The decision between anti-TNFs and anti-integrins as first-line treatment in CD depends on disease severity, safety concerns, and prescription coverage. Given the existing data on long-term outcomes and safety, anti-TNFs are often preferred to anti-integrins. Additional clinical experience and preferably prospective, head-to-head studies will be important to determine whether vedolizumab should be considered more often for first-line therapy in CD.
['Shivashankar|Raina|R|', 'Pardi|Darrell S|DS|']
D000068879:Adalimumab D061067:Antibodies, Monoclonal, Humanized D018501:Antirheumatic Agents D000068582:Certolizumab Pegol D003424:Crohn Disease D005765:Gastrointestinal Agents D006304:Health Status D006801:Humans D007155:Immunologic Factors D000069285:Infliximab D039441:Integrin alpha4 D039641:Integrin beta Chains D016023:Integrins D007412:Intestinal Fistula D060046:Maintenance Chemotherapy D000069442:Natalizumab D011788:Quality of Life D012074:Remission Induction D012720:Severity of Illness Index D016896:Treatment Outcome D014409:Tumor Necrosis Factor-alpha
Anti-integrins Treatment Crohn's disease Anti-TNFs Biologics